IL -17C Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-6xHis-Avi tag. The predicted molecular weight is 24-26 KDa and the accession number is Q9P0M4.

Human

HEK293 Cells

interleukin-17C,interleukin 17C,IL-17CMGC126884,IL-17C,IL17C,Cytokine CX2,CX2

His19-Val197

His19-Val197

Greater than 90% as determined by reducing SDS-PAGE. (QC verified)

Reconstitute the lyophilized protein in 4mM HCl. The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Interleukin 17C (IL 17C) is a 15 20 kDa glycosylated cytokine that plays an important role in mucosal immunity and chronic inflammation. IL 17C binds to IL 17 RE with high affinity and to IL 17 RA with low affinity. These two receptor chains can associate into a heterodimeric receptor for IL 17C. IL 17C expression is induced by inflammatory stimulation in colon and airway epithelial cells, keratinocytes, CD4+ T cells, macrophages, and dendritic cells. It is up regulated in various chronic inflammatory diseases including psoriasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). IL 17 RE is reciprocally down regulated in psoriatic lesions. The interaction of IL 17C with IL 17 RE promotes mucosal immunity through the induction of anti bacterial peptides and pro inflammatory cytokines and chemokines. IL 17C action supports the integrity of the colon epithelium following infection induced damage but also contributes to psoriatic skin thickening and the progression of arthritis. IL 17C is additionally up regulated in Th17 cell dependent autoimmunity. In this setting, it exacerbates disease severity by inducing Th17 cell production of IL 17A, IL 17F, IL 22, CCR6, and CCL20.